Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Aquestive Therapeutics Inc (AQST) USD0.001

Sell:$6.72 Buy:$6.74 Change: No change
Market closed |  Prices as at close on 23 November 2020 | Switch to live prices |
Sell:$6.72
Buy:$6.74
Change: No change
Market closed |  Prices as at close on 23 November 2020 | Switch to live prices |
Sell:$6.72
Buy:$6.74
Change: No change
Market closed |  Prices as at close on 23 November 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on the development of treatments for diseases related to the central nervous system (CNS). Its CNS programs consist of a pipeline of products that include Libervant, Sympazan, and AQST-117. Libervant is a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures. Sympazan is an oral soluble film formulation of clobazam for the treatment of seizures associated with a rare, intractable form of epilepsy known as Lennox-Gastaut Syndrome. AQST-117 is an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The Company’s complex molecule programs consist of AQST-108, and AQST-305, for the treatment of anaphylaxis and neuroendocrine tumors respectively. The Company also has a pipeline of products under partner programs, which includes Suboxone and APL-130277 for the treatment of opioid dependence, and Parkinson’s disease.

Contact details

Address:
30 Technology Dr
WARREN
07059-5166
United States
Telephone:
+1 (908) 9411900
Website:
https://aquestive.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
AQST
ISIN:
US03843E1047
Market cap:
$226.60 million
Shares in issue:
33.62 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Santo Costa
    Independent Chairman of the Board
  • Keith Kendall
    President, Chief Executive Officer, Director
  • John Cochran
    Vice Chairman of the Board
  • John Maxwell
    Senior Vice President, Chief Financial Officer
  • Daniel Barber
    Chief Operating Officer, Senior Vice President
  • Lori Braender
    Senior Vice President - General Counsel, Chief Compliance Officer and Corporate Secretary
  • Theresa Wood
    Senior Vice President - Human Resources and Organizational Development
  • Peter Boyd
    Senior Vice President - Business Process and Information Technology
  • Kenneth Marshall
    Senior Vice President - Chief Commercial Officer
  • Gary Slatko
    Senior Vice President, Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.